featured
Prediction of PFS in Patients With Advanced, Well-Differentiated, NETs Treated With a Somatostatin Analog
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
J. Clin. Oncol 2019 Aug 07;[EPub Ahead of Print], A Carmona-Bayonas, P Jiménez-Fonseca, Á Lamarca, J Barriuso, Á Castaño, M Benavent, V Alonso, MDC Riesco-Martínez, T Alonso-Gordoa, A Custodio, M Sánchez Cánovas, J Hernando Cubero, C López, A Lacasta, A Fernández Montes, M Marazuela, G Crespo, P Escudero, JÁ Diaz, E Feliciangeli, J Gallego, M Llanos, Á Segura, F Vilardell, JC Percovich, E Grande, J Capdevila, JW Valle, R García-CarboneroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.